HUTCHMED (HCM) Share Price, News & Analysis

Company Overview

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

Key Stats

• Today's Range: 261 to 269
• 50-Day Range: 245 to 325
• 52-Week Range: 190.40 to 353
• Volume: 39,973 shs
• Average Volume: 91,040 shs
• Market Capitalization: £2.26 billion
• P/E Ratio: N/A
• Dividend Yield: 4.63%
• Price Target: N/A
• Consensus Rating: N/A

HCM Stock Analysis - Frequently Asked Questions

How have HCM shares performed this year?

HUTCHMED's stock was trading at GBX 283 at the beginning of the year. Since then, HCM stock has decreased by 6.7% and is now trading at GBX 264.
View the best growth stocks for 2024 here.

How do I buy shares of HUTCHMED?

Shares of HCM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of HUTCHMED own?

Based on aggregate information from My MarketBeat watchlists, some other companies that HUTCHMED investors own include Intelsat (I), Associated British Foods (ABF), Chaarat Gold (CGH), Bank of America (BAC), Fossil Group (FOSL), AMC Entertainment (AMC) and Air Canada (AC).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: LON:HCM
• CUSIP: N/A
• CIK: N/A
• Web: www.chi-med.com
• Phone: +85221213888
• Fax: N/A
• Employees: 1,760
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 54.46
• P/E Growth: N/A
• Net Income: £-41,970,000.00
• Net Margins: -6.87%
• Pretax Margin: N/A
• Return on Equity: -5.44%
• Return on Assets: -5.90%

Debt

• Debt-to-Equity Ratio: 11.78
• Current Ratio: 2.81
• Quick Ratio: 2.97

Sales & Book Value

• Annual Sales: £610.81 million
• Price / Sales: 3.69
• Cash Flow: GBX 105.82 per share
• Price / Cash Flow: 2.49
• Book Value: GBX 87 per share
• Price / Book: 3.03

Miscellaneous

• Outstanding Shares: 854,440,000
• Free Float: N/A
• Market Cap: £2.26 billion
• Optionable: Not Optionable
• Beta: 0.76